Genetics

Molecular Templates (Nasdaq:MTEM) announced an agreement with Takeda Pharmaceutical for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma. The lead development candidate is a CD38-targeted ETB that resulted from a previous discovery collaboration between the two companies. As quoted in the press release: …

Molecular Templates (Nasdaq:MTEM) announced an agreement with Takeda Pharmaceutical for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma. The lead development candidate is a CD38-targeted ETB that resulted from a previous discovery collaboration between the two companies.

As quoted in the press release:

The parties developed preclinical stage ETBs targeting CD38 under the prior discovery collaboration. Takeda and Molecular Templates will further develop the ETBs for the treatment of multiple myeloma under this new license, development and commercialization agreement.

“This collaboration builds on Takeda’s deep history and commitment to the study of blood cancers, including multiple myeloma,” said Philip Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit at Takeda. “Throughout our research collaboration with Molecular Templates, we have seen the promise of its ETB platform for the discovery and development of new therapies. As we expand our relationship and continue to explore next-generation modalities, our hope is to bring forth new and important treatment options for patients.”

Under the terms of the agreement, Takeda will make an upfront payment of $30 million and Molecular Templates is eligible to receive development, regulatory and commercial milestone payments of up to $632.5 million if Molecular Templates exercises its co-development option or $337.5 million if Molecular Templates does not exercise or opts out of its co-development option. Takeda has also agreed to pay royalties on sales of the commercial product developed through the collaboration. Molecular Templates and Takeda will share equally in the development costs.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20595.89+4.91
TSXV846.29-0.92
DOW34168.09-129.64
S&P 5004349.93-6.52
NASD13542.12+2.82
ASX6961.60-177.90

COMMODITIES

Commodities
Gold1819.45-30.09
Silver23.54-0.35
Copper4.46-0.06
Palladium2331.00+144.00
Platinum1035.51+6.50
Oil87.36+0.01
Heating Oil2.690.00
Natural Gas4.280.00

DOWNLOAD FREE REPORTS

×